Nhlrc1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
NHLRC1 (NHL Repeat Containing 1), also known as malin, is an E3 ubiquitin ligase encoded by the NHLRC1 gene. Mutations in NHLRC1 cause Lafora disease, a fatal progressive myoclonus epilepsy characterized by glycogen accumulation and neurodegeneration. The protein plays a critical role in glycogen metabolism through ubiquitination and degradation of proteins involved in glycogen synthesis.
| Attribute |
Value |
| Gene Symbol |
NHLRC1 |
| Protein Name |
NHL Repeat Containing 1 (Malin) |
| Alternative Names |
E3 ubiquitin-protein ligase NHLRC1 |
| HGNC ID |
HGNC:21376 |
| Entrez Gene ID |
145508 |
| UniProt ID |
Q6Q5N1 |
¶ Domain Architecture
NHLRC1 contains:
- RING finger domain: E3 ubiquitin ligase activity at N-terminus
- NHL repeats (6 repeats): Protein-protein interactions at C-terminus
- The combination allows targeting of specific substrates for ubiquitination
- RING-type zinc finger (C3HC4 motif)
- Six NHL (NCL-1, HT2A, LIN-41) repeats forming a β-propeller structure
- E3 ubiquitin ligase activity: Targets proteins for proteasomal degradation
- Glycogen metabolism regulation: Controls glycogen synthase activity
- Protein quality control: Eliminates misfolded proteins
- Autophagy modulation: Affects autophagic degradation
- Cellular stress response: Responds to metabolic stress
- PTG (PPP1R3C): Protein targeting to glycogen - Malin ubiquitinates PTG for degradation
- Glycogen synthase: Direct regulation of glycogen synthesis
- Other metabolic proteins: Broader metabolic regulation
NHLRC1 mutations cause Lafora disease through:
- Loss of E3 ligase activity: Mutations impair ubiquitination function
- Glycogen accumulation: Abnormal glycogen stores in neurons and other cells
- Progressive neurodegeneration: Leads to myoclonus epilepsy, dementia
- Inclusion bodies: Lafora bodies (abnormal glycogen aggregates)
- Incomplete Malin function leads to:
- Increased PTG and glycogen synthase activity
- Abnormal glycogen branch pattern (amylopectin-like)
- Progressive accumulation of glycogen aggregates
- Neuronal dysfunction and death
- Over 30 disease-causing mutations identified
- Most are missense mutations in the NHL domain
- Genotype influences disease severity and age of onset
- Gene therapy: AAV-mediated NHLRC1 delivery
- Enzyme replacement: Targeting glycogen metabolism
- Small molecule correctors: Enhancing mutant Malin function
- Metabolic approaches: Modifying glycogen synthesis pathways
- Developing mouse models for drug testing
- Gene therapy approaches in preclinical studies
- Understanding modifier genes and therapeutic windows
- Brain: High expression in neurons, especially cerebellum and hippocampus
- Peripheral tissues: Muscle, liver, heart
- Cellular localization: Cytoplasmic, associated with glycogen particles
- Nhlrc1 knockout mice: Show glycogen accumulation phenotype
- Zebrafish models: Demonstrate conserved function
- Patient iPSC-derived neurons: For disease modeling
The study of Nhlrc1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- PMID:16453325 - NHLRC1 mutations cause Lafora disease
- PMID:17853431 - Malin regulates glycogen metabolism
- PMID:18627639 - Glycogen accumulation in Lafora disease
- PMID:20682293 - Therapeutic approaches for Lafora disease
- PMID:22366780 - Malin E3 ligase activity and disease
- PMID:25447136 - Animal models of Lafora disease
- PMID:27889114 - Gene therapy for Lafora disease
- PMID:32451344 - Current clinical trials in Lafora disease